These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35441534)

  • 1. Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection.
    Li L; Zheng W; Wang J; Han J; Guo Z; Hu Y; Li X; Zhou J
    AJR Am J Roentgenol; 2022 Sep; 219(3):434-443. PubMed ID: 35441534
    [No Abstract]   [Full Text] [Related]  

  • 2. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
    Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
    AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
    [No Abstract]   [Full Text] [Related]  

  • 3. Contrast-Enhanced Ultrasound With Perfluorobutane for Hepatocellular Carcinoma Diagnosis: Comparison of Imaging Phases and Diagnostic Criteria.
    Kang HJ; Lee JM; Yoon JH; Yoo J; Kim JH; Park J
    AJR Am J Roentgenol; 2024 Feb; 222(2):e2330156. PubMed ID: 37991335
    [No Abstract]   [Full Text] [Related]  

  • 4. Contrast-enhanced US with Sulfur Hexafluoride and Perfluorobutane: LI-RADS for Diagnosing Hepatocellular Carcinoma.
    Li L; Zou X; Zheng W; Li Y; Xu X; Li K; Su Z; Han J; Li Q; Zuo Y; Xie S; Wen H; Wang J; Guo Z; Zou R; Zhou J
    Radiology; 2023 Aug; 308(2):e230150. PubMed ID: 37642573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system.
    Li J; Ling W; Chen S; Ma L; Yang L; Lu Q; Luo Y
    Eur J Radiol; 2019 Nov; 120():108685. PubMed ID: 31606712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.
    Xian MF; Huang Y; Xie WX; Pan KM; Zeng D; Huang H; Li MD; Xie XY; Kuang M; Lu MD; Chen LD; Wang W
    AJR Am J Roentgenol; 2022 Jul; 219(1):76-85. PubMed ID: 34910538
    [No Abstract]   [Full Text] [Related]  

  • 7. Perfluorobutane-enhanced ultrasonography with a Kupffer phase: improved diagnostic sensitivity for hepatocellular carcinoma.
    Hwang JA; Jeong WK; Kang HJ; Lee ES; Park HJ; Lee JM
    Eur Radiol; 2022 Dec; 32(12):8507-8517. PubMed ID: 35705829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-individual comparison of Sonazoid contrast-enhanced ultrasound and SonoVue contrast-enhanced ultrasound in diagnosing hepatocellular carcinoma.
    Guo D; Wan W; Bai X; Wen R; Peng J; Lin P; Liao W; Huang W; Liu D; Peng Y; Kang T; Yang H; He Y
    Abdom Radiol (NY); 2024 May; 49(5):1432-1443. PubMed ID: 38584190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
    Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies.
    Wen R; Huang F; Lin P; Gao R; Pang J; Wu Y; Yin H; Tang Z; Ma Z; He Y; Yang H
    Abdom Radiol (NY); 2023 Dec; 48(12):3688-3695. PubMed ID: 37726380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?
    Ghadimi M; Birnbaum J; Kamel IR; Sirlin CB; Chernyak V
    Eur Radiol; 2022 May; 32(5):3327-3333. PubMed ID: 34807269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological considerations of CEUS LI-RADS: correlation with fibrosis stage and tumour histological grade.
    Cheng MQ; Hu HT; Huang H; Pan JM; Xian MF; Huang Y; Kuang M; Xie XY; Li W; Wang W; Lu MD
    Eur Radiol; 2021 Aug; 31(8):5680-5688. PubMed ID: 33502556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance for malignant progression of LI-RADS version 2017 category 3/4 nodules using contrast-enhanced ultrasound.
    Huang H; Li CQ; He DN; Ruan SM; Li MD; Cheng MQ; Lu MD; Kuang M; Wang W; Wang Y; Chen LD
    Eur Radiol; 2023 Dec; 33(12):9336-9346. PubMed ID: 37405501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.
    Vidili G; Arru M; Solinas G; Calvisi DF; Meloni P; Sauchella A; Turilli D; Fabio C; Cossu A; Madeddu G; Babudieri S; Zocco MA; Iannetti G; Di Lembo E; Delitala AP; Manetti R
    World J Gastroenterol; 2022 Jul; 28(27):3488-3502. PubMed ID: 36158272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Value of CEUS LI-RADS combined with AFP in early diagnosis of hepatocellular carcinoma in low- and high-risk patients.
    Wu Y; Chen Y; Wei L; Ding Z; Zhao S; Bao S; Tang J; Li H; Liu J; Zhu S
    J Cancer Res Ther; 2024 Aug; 20(4):1274-1283. PubMed ID: 38958652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.